Meeting
2024 ASCO Annual Meeting
A phase 1/2 study of BDC-3042, a novel dectin-2 agonistic antibody, in patients with advanced cancers.
Authors
Mohamad Adham Salkeni
NEXT Oncology, Fairfax, VA
Mohamad Adham Salkeni , Andrae L. Vandross , Ecaterina Elena Dumbrava , Antonio Giordano , Christopher Chen , Justin Kenkel , Danlin Cai , Lu Xu , Michael N. Alonso , Shelley Ackerman , Tai Yu , Dawn E. Colburn , Edith A. Perez , Sharon Wilks
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT06052852
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS2695)
DOI
10.1200/JCO.2024.42.16_suppl.TPS2695
Abstract #
TPS2695
Poster Bd #
161a
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I/II dose-escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.
First Author: John D. Powderly II
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I/II dose escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.
First Author: William Ho
Poster
2024 ASCO Annual Meeting
An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, and pharmacokinetics of VIP236 monotherapy in patients with advanced cancer.
First Author: Andrae L. Vandross
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update.
First Author: Neil Howard Segal